Lisata Therapeutics (NASDAQ:LSTA) Trading Down 3.6% – Here’s Why

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares fell 3.6% during mid-day trading on Thursday . The company traded as low as $2.06 and last traded at $2.12. Approximately 54,171 shares were traded during mid-day trading, a decline of 25% from the average session volume of 71,772 shares. The stock had previously closed at $2.20.

Analyst Upgrades and Downgrades

LSTA has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright downgraded Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Price Performance

The business has a fifty day moving average of $3.32 and a 200-day moving average of $3.78. The stock has a market capitalization of $19.31 million, a price-to-earnings ratio of -1.14 and a beta of 0.79.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter. As a group, research analysts anticipate that Lisata Therapeutics, Inc. will post -1.09 EPS for the current year.

Institutional Trading of Lisata Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cerity Partners LLC acquired a new stake in Lisata Therapeutics during the second quarter valued at approximately $32,000. CIBC Bancorp USA Inc. acquired a new position in Lisata Therapeutics in the third quarter worth approximately $37,000. SOL Capital Management CO bought a new position in shares of Lisata Therapeutics in the first quarter valued at $61,000. Ground Swell Capital LLC increased its holdings in shares of Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after buying an additional 15,213 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after acquiring an additional 7,093 shares during the last quarter. 8.94% of the stock is currently owned by institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.